Product data sheet

MedKoo Cat#: 201572 Name: Saridegib free base CAS#: 1037210-93-7 (free base) Chemical Formula: $C_{29}H_{48}N_2O_3S$ Exact Mass: 504.3386 Molecular Weight: 504.77	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years.
	In solvent: -80°C 3 months; -20°C 2 weeks.

1. Product description:
Saridegib, also known as Patidegip and IPI-926, is an orally bioavailable, cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway with potential antineoplastic activity. Saridegib binds to and inhibits the cell membrane-spanning G-protein coupled receptor Smoothened (Smo), which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival.

2. CoA, QC data, SDS, and handling instruction
SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	10	19.81

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	**1 mg**	**5 mg**	**10 mg**
1 mM	1.98 mL	9.91 mL	19.81 mL
5 mM	0.40 mL	1.98 mL	3.96 mL
10 mM	0.20 mL	0.99 mL	1.98 mL
50 mM	0.04 mL	0.20 mL	0.40 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator
Please refer the product web page under section of "Calculator"

6. Recommended literature which reported protocols for in vitro and in vivo study
In vitro study

1. Ma H, Tian Y, Yu X. Targeting Smoothened Sensitizes Gastric Cancer to Chemotherapy in Experimental Models. Med Sci Monit. 2017 Mar 28;23:1493-1500. doi: 10.12659/msm.903012. PMID: 28350784; PMCID: PMC5381338.
2. Lin TL, Wang QH, Brown P, Peacock C, Merchant AA, Brennan S, Jones E, McGovern K, Watkins DN, Sakamoto KM, Matsui W. Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS One. 2010 Dec 28;5(12):e15262. doi: 10.1371/journal.pone.0015262. PMID: 21203400; PMCID: PMC3011010.

In vivo study

1. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar;45(3):370-5. doi: 10.1097/MPA.0000000000000458. PMID: 26390428; PMCID: PMC5908466.
2. Bowles DW, Keysar SB, Eagles JR, Wang G, Glogowska MJ, McDermott JD, Le PN, Gao D, Ray CE, Rochon PJ, Roop DR, Tan AC, Serracino HS, Jimeno A. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2016 Feb;53:74-9. doi: 10.1016/j.oraloncology.2015.11.014. Epub 2015 Dec 15. PMID: 26705064; PMCID: PMC5676309.

Product data sheet

7. Bioactivity

Biological target:

Saridegib is a potent and specific Smo inhibitor.

In vitro activity

Saridegib potential therapeutic agent for human B-cell acute lymphocytic leukemia (B-ALL). The expression of Hh pathway components was common in B-ALL cell lines and clinical samples. Saridegib modulated Hh pathway activity in B-ALL cells. The primary impact of inhibiting this pathway activity was on highly clonogenic B-ALL cells that expressed aldehyde dehydrogenase (ALDH), limiting their self-renewal potential.

Reference: PLoS One. 2010 Dec 28;5(12):e15262. https://pubmed.ncbi.nlm.nih.gov/21203400/

In vivo activity

This study evaluated saridegib in combination with FOLFIRINOX in patients with advanced pancreatic cancer. The objective response rate was high (67%), and patients receiving saridegib maintenance showed further declines in CA19-9 levels even after FOLFIRINOX discontinuation. Treatment did not result in consistent increases in tumor perfusion. This study closed early when a separate phase II trial of saridegib plus gemcitabine indicated detrimental effects of this combination.

Reference: Pancreas. 2016 Mar;45(3):370-5. https://pubmed.ncbi.nlm.nih.gov/26390428/

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.